We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NEW GUIDANCE ON POSTAPPROVAL MANUFACTURING CHANGES
NEW GUIDANCE ON POSTAPPROVAL MANUFACTURING CHANGES
May 3, 2004
Major changes in the drug industry combined with increased demand for new drug therapies has prompted the FDA to issue a revised guidance to help the pharmaceutical industry determine how they should report postapproval manufacturing changes for new drug applications (NDAs) and abbreviated new drug applications (ANDAs).